Chang Hoon Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chang Hoon Han has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Seng Chan You
Yonsei Institute for Digital Health, Yonsei University, Seoul, Korea
4 shared publications - Hamin Kim
Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Jong Deok Kim
Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Kyung Won Kim
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea
3 shared publications - Mireu Park
Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Soo Yeon Kim
Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Background: Ticagrelor and prasugrel are recommended P2Y 12 inhibitors for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), yet uncertainty persists regarding their direct comparative evidence and guideline recommendations differ. Methods: We conducted a multinational retrospective new-user cohort study across 7 claims and electronic health record databases. Adults with ACS undergoing first PCI who initiated ticagrelor or prasugrel were included; patients with prior major ischemic or hemorrhagic events or oral anticoagulant use were excluded. The primary outcome was 1-year major adverse cardiovascular events (MACE: all-cause mortality, acute myocardial infarction, or stroke). Secondary outcomes included net adverse clinical events (NACE) and individual components. Propensity scores were estimated using large-scale L1-regularized logistic regression and applied through stratification. Prespecified diagnostics (covariate balance, empirical equipoise, and systematic error) determined eligibility of each database for inclusion in meta-analysis. Database-specific hazard ratios (HRs) were combined using Bayesian random-effects meta-analysis. Results: Among 7 participating databases, 3 met prespecified diagnostic criteria and were included in the primary meta-analysis, comprising 133,718 patients from one nationwide Korean claims database and two U.S. commercial claims databases (ticagrelor, 109,639; prasugrel, 24,079). For 1-year MACE, the pooled HR for ticagrelor versus prasugrel was 1.28 (95% credible interval [CrI], 0.89-1.88), with substantial between-database heterogeneity. Sensitivity analyses across alternative time-at-risk definitions and propensity score matching were consistent. No statistically credible differences were observed for NACE (HR 1.23, CrI 0.88-1.75), all-cause mortality (HR 1.17, CrI 0.78-1.77), cardiovascular mortality (HR 1.23, CrI 0.81-1.87), ischemic events (HR 1.28, CrI 0.88-1.90), hemorrhagic events (HR 1.01, CrI 0.72-1.39), acute myocardial infarction (HR 1.30, CrI 0.88-1.94), stroke (HR 1.09, CrI 0.73-1.58), or gastrointestinal bleeding (HR 1.04, CrI 0.77-1.41). In a post hoc meta-analysis restricted to the two U.S. databases, the pooled HR for 1-year MACE was 1.49 (95% CrI 1.05-2.10). Conclusions: In this pre-specified multinational observational study, no statistically credible difference in 1-year MACE was observed between ticagrelor and prasugrel in patients with ACS undergoing PCI. However, substantial cross-database heterogeneity warrants further investigation into context-specific comparative effectiveness and safety.
Open AccessComparative Effectiveness of Ticagrelor vs. Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Background: Ticagrelor and prasugrel are recommended P2Y 12 inhibitors for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), yet uncertainty persists regarding their direct comparative evidence and guideline recommendations differ. Methods: We conducted a multinational retrospective new-user cohort study across 7 claims and electronic health record databases. Adults with ACS undergoing first PCI who initiated ticagrelor or prasugrel were included; patients with prior major ischemic or hemorrhagic events or oral anticoagulant use were excluded. The primary outcome was 1-year major adverse cardiovascular events (MACE: all-cause mortality, acute myocardial infarction, or stroke). Secondary outcomes included net adverse clinical events (NACE) and individual components. Propensity scores were estimated using large-scale L1-regularized logistic regression and applied through stratification. Prespecified diagnostics (covariate balance, empirical equipoise, and systematic error) determined eligibility of each database for inclusion in meta-analysis. Database-specific hazard ratios (HRs) were combined using Bayesian random-effects meta-analysis. Results: Among 7 participating databases, 3 met prespecified diagnostic criteria and were included in the primary meta-analysis, comprising 133,718 patients from one nationwide Korean claims database and two U.S. commercial claims databases (ticagrelor, 109,639; prasugrel, 24,079). For 1-year MACE, the pooled HR for ticagrelor versus prasugrel was 1.28 (95% credible interval [CrI], 0.89-1.88), with substantial between-database heterogeneity. Sensitivity analyses across alternative time-at-risk definitions and propensity score matching were consistent. No statistically credible differences were observed for NACE (HR 1.23, CrI 0.88-1.75), all-cause mortality (HR 1.17, CrI 0.78-1.77), cardiovascular mortality (HR 1.23, CrI 0.81-1.87), ischemic events (HR 1.28, CrI 0.88-1.90), hemorrhagic events (HR 1.01, CrI 0.72-1.39), acute myocardial infarction (HR 1.30, CrI 0.88-1.94), stroke (HR 1.09, CrI 0.73-1.58), or gastrointestinal bleeding (HR 1.04, CrI 0.77-1.41). In a post hoc meta-analysis restricted to the two U.S. databases, the pooled HR for 1-year MACE was 1.49 (95% CrI 1.05-2.10). Conclusions: In this pre-specified multinational observational study, no statistically credible difference in 1-year MACE was observed between ticagrelor and prasugrel in patients with ACS undergoing PCI. However, substantial cross-database heterogeneity warrants further investigation into context-specific comparative effectiveness and safety.
- Open Access
- 25 June 2026
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 180, 105071
ARKE: An ontology-driven framework for automated mapping of local radiology procedure terms to the LOINC-RadLex playbook using large language model
- 25 June 2026
- Published by Elsevier in Journal of Biomedical Informatics
- Vol. 180, 105071
Open AccessARKE: An ontology-driven framework for automated mapping of local radiology procedure terms to the LOINC-RadLex playbook using large language model
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (2) , e55
Erratum: Correction of Figures in the Article “Validation of the Phoenix Criteria for Sepsis and Septic Shock in a Pediatric Intensive Care Unit”.
Han CH, et al. J Korean Med Sci. 2026 Jan;41:e55. https://doi.org/10.3346/jkms.2026.41.e55
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (2) , e55
Open AccessErratum: Correction of Figures in the Article “Validation of the Phoenix Criteria for Sepsis and Septic Shock in a Pediatric Intensive Care Unit”.
Han CH, et al. J Korean Med Sci. 2026 Jan;41:e55. https://doi.org/10.3346/jkms.2026.41.e55
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (10) , e106
Validation of the Phoenix Criteria for Sepsis and Septic Shock in a Pediatric Intensive Care Unit
Han CH, et al. J Korean Med Sci. 2025 Mar;40:e106. https://doi.org/10.3346/jkms.2025.40.e106
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (10) , e106
Open AccessValidation of the Phoenix Criteria for Sepsis and Septic Shock in a Pediatric Intensive Care Unit
Han CH, et al. J Korean Med Sci. 2025 Mar;40:e106. https://doi.org/10.3346/jkms.2025.40.e106
- Open Access
- 1 January 2023
- Published by XMLink in Yonsei Medical Journal
- Vol. 64 (6) , 384-394
Radiologic Assessment of Lung Edema Score as a Predictor of Clinical Outcome in Children with Acute Respiratory Distress Syndrome
Han CH, et al. Yonsei Med J. 2023 Jun;64(6):384-394. https://doi.org/10.3349/ymj.2022.0653
- 1 January 2023
- Published by XMLink in Yonsei Medical Journal
- Vol. 64 (6) , 384-394
Open AccessRadiologic Assessment of Lung Edema Score as a Predictor of Clinical Outcome in Children with Acute Respiratory Distress Syndrome
Han CH, et al. Yonsei Med J. 2023 Jun;64(6):384-394. https://doi.org/10.3349/ymj.2022.0653